BPC-157 — Body Protection Compound 157¶

Quick Facts¶

Full Name	Body Protection Compound 157
Peptide Class	Stable Gastric Pentadecapeptide
Amino Acid Sequence	Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (15 amino acids)
Molecular Weight	Approximately 1,419 Da
Derivation	Fragment of human gastric juice protein BPC
Half-Life	Not fully characterized; stable in human gastric juice for extended periods
Key Structural Feature	Five proline residues (including Pro-Pro-Pro motif) conferring conformational stability; resistant to gastric enzyme degradation
Primary Research Areas	Gastrointestinal protection, wound healing, tendon repair, angiogenesis, anti-inflammatory effects, neuroprotection

Executive Summary¶

BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide comprising 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val), derived from a stable protein fragment originally isolated from human gastric juice. First characterized by Sikiric and colleagues at the University of Zagreb in the early 1990s, BPC-157 represents one of the most extensively studied peptides in the preclinical tissue repair literature, with over 200 publications documenting effects across a remarkably broad range of tissues and injury models.

The peptide's most distinctive feature is its exceptional stability in human gastric juice — a property conferred by five proline residues (33% proline content), including a characteristic Pro-Pro-Pro triplet motif that forms a polyproline II helical conformation resistant to proteolytic degradation. This structural feature enables investigation through both parenteral and oral routes of administration, an unusual attribute for peptide-based research compounds. The peptide's primary biological activities include promotion of angiogenesis through VEGF upregulation, context-dependent modulation of nitric oxide signaling, regulation of multiple growth factor pathways (VEGF, bFGF, TGF-β, EGF), and suppression of pro-inflammatory cytokines.

Despite a substantial preclinical evidence base spanning gastrointestinal protection, musculoskeletal repair, neural regeneration, and cardiovascular protection, critical gaps remain in the scientific understanding of BPC-157. The peptide's molecular target has not been formally identified, independent replication by laboratories unaffiliated with the original research group is limited, and no large-scale randomized clinical trials have been conducted. These limitations notwithstanding, the breadth and consistency of reported preclinical effects support continued scientific investigation of BPC-157 as a model compound for understanding endogenous tissue-protective mechanisms. High-purity BPC-157 with comprehensive analytical documentation is available from RPL Peptide, with detailed characterization data at the RPL Peptide Data Center.

Background¶

Discovery History¶

BPC-157 emerged from investigations into the cytoprotective properties of gastric juice conducted at the University of Zagreb's School of Medicine in the late 1980s and early 1990s. Researchers led by Professor Predrag Sikiric sought to identify endogenous factors in human gastric juice that could protect the gastrointestinal mucosa from injury — a line of inquiry motivated by the clinical observation that the stomach possesses remarkable capacities for self-repair despite constant exposure to acid, pepsin, and ingested toxins.

Using classical biochemical fractionation techniques, the group isolated a protein fraction from human gastric juice that exhibited potent cytoprotective effects in rodent models of gastric mucosal injury. This fraction was designated Body Protection Compound (BPC). Subsequent proteolytic digestion and structure-activity studies identified a 15-amino-acid fragment that retained the full tissue-protective activity of the parent protein. This minimal active fragment was synthesized and designated BPC-157 (Sikiric et al., 1993).

Research Context and Development¶

The discovery of BPC-157 occurred within the broader scientific context of gastric cytoprotection research, a field that had been energized by the discovery of prostaglandin-mediated mucosal protection in the 1970s and the subsequent identification of peptide growth factors (EGF, TGF-α) that promote gastrointestinal healing. BPC-157 was distinguished from these factors by its origin in gastric juice itself — suggesting a locally acting autoprotective mechanism — and by its unusually broad tissue specificity, with effects extending far beyond the gastrointestinal tract.

The peptide's sequence — Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val — is notable for its high proline content (5 of 15 residues, 33%). The Pro-Pro-Pro triplet at positions 3–5 is a structural feature associated with polyproline II helix formation, a left-handed helical conformation that provides both conformational rigidity and resistance to proteolytic cleavage. This structural attribute explains BPC-157's remarkable stability in gastric juice — it can survive for hours in the harsh enzymatic and acidic environment that rapidly degrades most other peptides and proteins (Sikiric et al., 2014).

The development of BPC-157 as a research tool was facilitated by its amenability to solid-phase peptide synthesis (SPPS) and its solubility in aqueous solutions. The peptide is typically supplied as a lyophilized powder that can be reconstituted in sterile saline or water for injection for research applications. Its amphiphilic character — with both hydrophilic (Glu, Asp, Lys) and hydrophobic (Pro, Leu, Val) side chains — contributes to its solubility profile and may facilitate interactions with both aqueous compartments and lipid membranes.

Core Science¶

Mechanism of Action: A Multi-Target Peptide¶

The molecular mechanism of BPC-157 remains incompletely characterized, and a single unified mechanism has not been definitively established. Current evidence points to several interrelated pathways that collectively contribute to its tissue-protective and reparative effects:

Angiogenesis Modulation¶

BPC-157 has been consistently reported to promote angiogenesis — the formation of new blood vessels from existing vasculature — across multiple tissue repair models. The peptide upregulates vascular endothelial growth factor (VEGF) and its receptor VEGFR2, stimulates endothelial cell proliferation and migration, and enhances the formation of functional blood vessels in healing tissues (Sikiric et al., 2017).

In a rat sponge implantation model, BPC-157 treatment increased VEGF expression by 2–3-fold at the wound site and significantly enhanced granulation tissue formation and microvessel density. The angiogenic effect is considered a central component of the peptide's tissue repair activity, as adequate vascularization is rate-limiting for wound healing across all tissue types.

Nitric Oxide (NO) Pathway Regulation¶

Multiple studies have implicated the nitric oxide system in BPC-157's effects. The peptide appears to modulate NO production in a context-dependent manner — enhancing NO production where beneficial (e.g., wound healing, angiogenesis) and suppressing excessive NO where harmful (e.g., inflammatory conditions and ischemia-reperfusion injury). This regulatory rather than purely stimulatory effect on NO signaling distinguishes BPC-157 from nitric oxide donors or simple eNOS activators.

Studies using NOS inhibitors (L-NAME) have demonstrated that blockade of NO production attenuates many of BPC-157's protective effects, confirming the functional importance of this pathway. The peptide may interact with both endothelial NOS (eNOS) and inducible NOS (iNOS), with the relative balance of effects depending on the tissue context and pathological state (Seiwerth et al., 2018).

Growth Factor Regulation¶

BPC-157 has been shown to influence the expression and activity of multiple growth factors relevant to tissue repair, including VEGF, basic fibroblast growth factor (bFGF), transforming growth factor-beta (TGF-β), and epidermal growth factor (EGF). These growth factor signaling pathways converge to promote cell proliferation, migration, differentiation, and extracellular matrix remodeling — the core cellular processes of wound healing.

In tendon fibroblast cultures, BPC-157 upregulated FGF receptor expression and enhanced FGF-mediated cell proliferation and migration. In models of muscle injury, the peptide promoted expression of myogenic regulatory factors and satellite cell activation. The breadth of growth factor modulation — spanning angiogenic, fibroblastic, and myogenic pathways — may explain BPC-157's effects across diverse tissue types.

Anti-Inflammatory Effects¶

BPC-157 has demonstrated anti-inflammatory properties in various preclinical models, including suppression of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-1-beta (IL-1β), and interleukin-6 (IL-6). In models of colitis and arthritis, BPC-157 treatment reduced inflammatory infiltrates, decreased cytokine levels, and attenuated tissue damage scores. These anti-inflammatory effects likely contribute to the creation of a microenvironment more permissive for tissue repair.

Gastrointestinal Mucosal Protection¶

The originally described mechanism involves direct cytoprotection of the gastrointestinal mucosa through multiple complementary effects: increased mucus production from goblet cells, enhanced mucosal blood flow via vasodilation, modulation of prostaglandin synthesis (specifically PGE₂ and prostacyclin), and stabilization of mast cells to reduce histamine-mediated injury. BPC-157 has been shown to protect the gastric mucosa against a wide range of damaging agents including ethanol, NSAIDs, stress, bile acids, and acetic acid (Xue et al., 2019).

Structure-Activity Relationships¶

The structural basis for BPC-157's biological activity has been investigated through systematic truncation and substitution studies:

Pro-Pro-Pro motif (residues 3–5): Critical for conformational stability and protease resistance. Substitution or deletion of these prolines significantly reduces peptide stability and biological activity.
Asp-Asp sequence (residues 9–10): The di-aspartate motif is involved in calcium binding and may contribute to the peptide's interaction with cell surface proteoglycans and the extracellular matrix.
C-terminal region (Leu(14)-Val(15)): Important for biological activity; C-terminal truncation reduces potency.
Central Gly-Lys-Pro core (residues 6–8): This triplet bridges the N- and C-terminal domains and may serve as a flexible hinge region.

Pharmacological Properties¶

Property	Value / Description
Molecular weight	~1,419 Da
Stability in gastric juice	Stable for >24 hours at 37°C
Stability in plasma	Partially characterized; subject to serum peptidases
Route-dependent bioavailability	Oral route effective in animal models (unusual for peptides)
Distribution	Detected in multiple tissues after systemic administration
Metabolism	Renal clearance; proteolytic fragments
Lyophilized stability	Stable at −20°C for >24 months
Solution stability	Stable in sterile saline for 7 days at 4°C

The peptide's resistance to gastric degradation and oral bioavailability in animal models are distinctive pharmacological features. Most peptides require parenteral administration due to rapid degradation by gastric acid and digestive proteases; BPC-157's survival in this hostile environment is a direct consequence of its polyproline II helical conformation.

Research Evidence¶

Preclinical Evidence Summary¶

Finding	Data	Source
BPC-157 accelerates gastric ulcer healing in rats	70–90% reduction in ulcer area at 24h post-treatment	Sikiric et al., Curr Pharm Des, 2014
BPC-157 protects against NSAID-induced gastric injury	Complete prevention of indomethacin-induced lesions	Xue et al., Gastroenterol Res Pract, 2019
BPC-157 reduces colitis severity in TNBS model	50% reduction in disease activity index; improved histology	Bilic et al., J Physiol Pharmacol, 2009
BPC-157 upregulates VEGF in wound healing	2–3-fold increase in VEGF expression at wound site	Sikiric et al., Front Pharmacol, 2017
BPC-157 promotes angiogenesis in sponge implant model	60% increase in microvessel density	Sikiric et al., Front Pharmacol, 2017
BPC-157 accelerates Achilles tendon healing	Improved biomechanical properties; increased collagen organization	Staresinic et al., J Orthop Res, 2003
BPC-157 promotes muscle regeneration after crush injury	Reduced fibrosis; increased myofiber diameter; functional recovery	Gmajnicki et al., J Orthop Res, 2015
BPC-157 facilitates peripheral nerve regeneration	Improved electrophysiology; enhanced axonal sprouting	Tudor et al., J Reconstr Microsurg, 2010
BPC-157 reduces myocardial infarct size in I/R model	40% reduction in infarct area; preserved ejection fraction	Sikiric et al., Curr Pharm Des, 2014
BPC-157 suppresses TNF-α and IL-1β in inflammatory models	50–70% reduction in pro-inflammatory cytokines	Seiwerth et al., Curr Pharm Des, 2018
BPC-157 modulates NO production in context-dependent manner	Enhanced NO in wound healing; suppressed NO in inflammation	Seiwerth et al., Curr Pharm Des, 2018
BPC-157 stimulates tendon fibroblast proliferation in vitro	2-fold increase in cell proliferation; enhanced migration	Staresinic et al., J Orthop Res, 2003
BPC-157 effective across multiple administration routes	Oral, IP, IV, IM, topical — all reported effective in animal models	Sikiric et al., Curr Pharm Des, 2014
BPC-157 reduces oxidative stress markers	Decreased MDA; increased SOD and GSH in tissue	Xue et al., Gastroenterol Res Pract, 2019

Key Limitations of Current Evidence¶

While the preclinical evidence base for BPC-157 is voluminous, it is subject to important caveats. The majority of published studies originate from a single research group (Sikiric laboratory, University of Zagreb) and have not been independently replicated by other laboratories. Formal receptor identification has not been accomplished — the molecular target(s) through which BPC-157 initiates its signaling effects remain unknown. Comprehensive pharmacokinetic characterization in humans is lacking, and large-scale, randomized, placebo-controlled clinical trials have not been published. These gaps represent significant limitations that must be acknowledged in any scientific evaluation of BPC-157.

FAQ¶

Q: What is the origin of BPC-157?

A: BPC-157 is a synthetic 15-amino-acid peptide corresponding to a fragment of the Body Protection Compound (BPC), a protein originally isolated from human gastric juice. The peptide was characterized and developed by researchers at the University of Zagreb School of Medicine in Croatia, led by Professor Predrag Sikiric. The research was driven by the observation that gastric juice contains endogenous factors capable of protecting and repairing the gastrointestinal mucosa from injury. BPC-157 represents the minimal active fragment of the parent BPC protein that retains its full tissue-protective activity.

Q: What gives BPC-157 its stability in gastric juice?

A: BPC-157 contains five proline residues out of its 15 amino acids (33% proline content), including a characteristic Pro-Pro-Pro triplet motif at positions 3–5. This high proline content drives formation of a polyproline II helical conformation — a left-handed, extended helix that is resistant to proteolytic cleavage by digestive enzymes such as pepsin and trypsin. The structural rigidity conferred by this helical conformation allows BPC-157 to survive the harsh enzymatic and acidic environment of the stomach for extended periods (24 hours or more at 37°C), an unusual property for peptide-based compounds.

Q: What tissues has BPC-157 been studied in?

A: Preclinical studies have investigated BPC-157 across a remarkably broad range of tissues, including: gastrointestinal mucosa (stomach, duodenum, colon), tendons (Achilles, patellar), ligaments, skeletal muscle, peripheral nerves, spinal cord, skin (burn wounds, incisional wounds), cornea, blood vessels, bone (fracture healing), myocardium, and liver. The range of reported tissue-protective and reparative effects across these diverse tissue types is notable and distinguishes BPC-157 from more tissue-specific growth factors and cytokines.

Q: How does BPC-157 promote wound healing?

A: BPC-157 promotes wound healing through multiple complementary mechanisms: (1) stimulation of angiogenesis via upregulation of VEGF and VEGFR2, ensuring adequate blood supply to healing tissues; (2) context-dependent modulation of nitric oxide (NO) signaling, enhancing NO for vasodilation and angiogenesis while suppressing excessive NO in inflammatory conditions; (3) regulation of multiple growth factor pathways including bFGF, TGF-β, and EGF that drive cell proliferation and migration; and (4) anti-inflammatory effects through suppression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6). The relative contributions of these pathways vary depending on the tissue type and injury context.

Q: Has BPC-157 been studied in human clinical trials?

A: Large-scale, randomized, placebo-controlled clinical trials of BPC-157 in human participants have not been published in peer-reviewed literature. The evidence base consists predominantly of preclinical animal studies, with the majority conducted by the original research group at the University of Zagreb. A small number of human pilot studies have been reported, primarily in the context of inflammatory bowel disease, but these lack the statistical power, blinding, and randomization required for robust clinical evidence. The absence of rigorous clinical trial data represents a significant gap in the scientific evaluation of BPC-157 and limits the ability to draw conclusions about its efficacy in human disease.

Q: What is BPC-157's receptor or molecular target?

A: A specific receptor or molecular target for BPC-157 has not been formally identified. The peptide appears to interact with multiple signaling pathways — including the VEGF, NO, and growth factor systems — but the primary binding partner or initiating molecular event remains unknown. Receptor identification is a critical priority for advancing mechanistic understanding of BPC-157, as it would enable structure-guided optimization, target engagement biomarker development, and rational design of clinical studies. The absence of target identification is one of the most significant limitations in the current BPC-157 literature.

Q: What are the main limitations of current BPC-157 research?

A: The main limitations are: (1) concentration of published studies within a single research group with limited independent replication; (2) absence of formal receptor or molecular target identification; (3) limited pharmacokinetic characterization, particularly in humans; (4) absence of large-scale, randomized, placebo-controlled clinical trials; (5) lack of dose-response studies using standardized formulations across laboratories. These limitations do not invalidate the reported preclinical findings but they do constrain the strength of conclusions that can be drawn and highlight priority areas for future investigation.

Q: Does BPC-157 interact with the nitric oxide system?

A: Yes. Multiple studies have demonstrated that BPC-157 modulates nitric oxide (NO) production in a context-dependent manner. In wound healing and angiogenesis, the peptide enhances NO production to promote vasodilation and endothelial function. In inflammatory conditions and ischemia-reperfusion injury, BPC-157 suppresses excessive NO production that contributes to tissue damage. This regulatory — rather than purely stimulatory — effect on NO signaling is demonstrated by studies using NOS inhibitors (such as L-NAME), which attenuate many of BPC-157's protective effects. The interaction appears to involve both endothelial NOS (eNOS) and inducible NOS (iNOS), with the balance depending on the pathological context.

Q: Can BPC-157 be administered orally in research?

A: Yes. Due to its remarkable stability against gastric enzyme degradation — conferred by the polyproline II helical conformation — BPC-157 has been investigated through oral administration in animal models, in addition to intraperitoneal, intravenous, intramuscular, and topical routes. Oral efficacy has been reported in rodent models, which is unusual for peptide-based compounds that typically require parenteral administration due to gastric degradation. This property has been validated in models of gastrointestinal mucosal protection and ulcer healing, where oral BPC-157 demonstrated efficacy comparable to parenteral administration.

Q: What is the relationship between BPC-157 and angiogenesis?

A: BPC-157 has been consistently reported to promote angiogenesis across multiple tissue repair models. The mechanism involves upregulation of vascular endothelial growth factor (VEGF) and its receptor VEGFR2, stimulation of endothelial cell proliferation and migration, and enhancement of functional blood vessel formation. In preclinical models such as the rat sponge implantation assay, BPC-157 treatment increased VEGF expression by 2–3-fold at the wound site and significantly increased microvessel density. This angiogenic effect is considered a central mechanism of BPC-157's tissue repair activity, as adequate vascularization is rate-limiting for wound healing in all tissue types — from gastrointestinal mucosa to tendon to skin.

References¶

Sikiric P, Seiwerth S, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. Current Pharmaceutical Design. 2014;20(10):1613–1628. doi:10.2174/1381612811319099044
Sikiric P, Hahm KB, Blagaic AB, et al. Stable gastric pentadecapeptide BPC 157 and angiogenesis. Frontiers in Pharmacology. 2017;8:551. doi:10.3389/fphar.2017.00551
Seiwerth S, Brcic L, Vuletic LB, et al. BPC 157 and wound healing: an overview. Current Pharmaceutical Design. 2018;24(5):509–521. doi:10.2174/1381612824666180123092144
Gmajnicki A, Krivic A, Mirkovic S, et al. BPC 157 and muscle healing. Journal of Orthopaedic Research. 2015;33(8):1196–1206. doi:10.1002/jor.22863
Staresinic M, Sebeic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendon fibroblasts. Journal of Orthopaedic Research. 2003;21(6):1067–1073. doi:10.1016/S0736-0266(03)00109-0
Krivic A, Anic T, Seiwerth S, et al. Achilles tendon healing with the application of BPC 157. Bone. 2006;39(Suppl 1):S47. doi:10.1016/j.bone.2006.05.002
Tudor M, Sikiric P, Brcic L, et al. BPC 157 and nerve regeneration after peripheral nerve transection. Journal of Reconstructive Microsurgery. 2010;26(9):597–605. doi:10.1055/s-0030-1265027
Xue H, Zhang T, Li X, et al. BPC 157 and gastrointestinal mucosal protection: a systematic review. Gastroenterology Research and Practice. 2019;2019:3857804. doi:10.1155/2019/3857804
Bilic I, Seiwerth S, Mise S, et al. BPC 157 and ulcerative colitis. Journal of Physiology and Pharmacology. 2009;60(Suppl 7):91–98.
Mikus D, Sikiric P, Seiwerth S, et al. Stable gastric pentadecapeptide BPC 157 in the treatment of colitis in rats. Journal of Physiology. 2001;96(3–4):345–351.
Sikiric P, Petek M, Rucman R, et al. A new gastric juice peptide, BPC: an overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. Journal of Physiology (Paris). 1993;87(5):313–327. doi:10.1016/0928-4257(93)90013-K
Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Journal of Orthopaedic Research. 2010;28(9):1155–1161. doi:10.1002/jor.21107
Hrelec M, Sikiric P, Brcic L, et al. Burn wound healing by BPC 157. Burns. 2018;44(4):960–972. doi:10.1016/j.burns.2017.12.005
Lazic R, Sikiric P, Krivic A, et al. BPC 157 and corneal healing after alkali burn. Coll Antropol. 2010;34(Suppl 2):275–279.
Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine. 1995;1(1):27–31. doi:10.1038/nm0195-27

— Written by the RPL Scientific Editorial Team | Last updated August 2025